Xitoglip 50mg Tablet contains Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for the management of type 2 diabetes mellitus. Sitagliptin works by enhancing the body's incretin system, which increases insulin release from pancreatic beta cells and decreases glucagon secretion from alpha cells in a glucose-dependent manner. This dual action helps to improve glycemic control by reducing fasting and postprandial blood glucose levels. Xitoglip is prescribed as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes, either as monotherapy or in combination with other antidiabetic agents such as metformin, sulfonylureas, or insulin. The recommended dose is 50mg once daily, with or without food. Sitagliptin is generally well tolerated, with a low risk of hypoglycemia when used alone. Common adverse effects may include headache, nasopharyngitis, and upper respiratory tract infections. Caution is advised in patients with renal impairment, and dosage adjustments may be necessary. Xitoglip should not be used in patients with type 1 diabetes or diabetic ketoacidosis. Regular monitoring of blood glucose and renal function is recommended during therapy to ensure optimal efficacy and safety.